Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer

Timothy Masterson, Bobby Shayegan, Brett S. Carver, Dean F. Bajorin, Darren R. Feldman, Robert J. Motzer, George J. Bosl, Joel Sheinfeld

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Integration of platinum-based chemotherapy and surgical resection of residual masses is essential in the management of advanced nonseminomatous germ cell tumors (NSGCT). We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival. Between 1989 and 2003, 532 patients with advanced NSGCT underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) with a median follow-up of 41 months. Survival probabilities were estimated by the KaplanMeier method. Cox proportional hazards regression analysis was used to determine the prognostic significance of risk factors for progression and survival. Of 532 patients, 402 (76%) underwent PC-RPLND alone, and 130 (24%) underwent resection of ERP residual disease concurrently or in a staged fashion within 6 weeks. Concordance between retroperitoneal (RP) and ERP sites of disease was 83% in the presence of fibrosis, 42% for teratoma, and 47% for viable NSGCT. Overall, 34% of patients undergoing resection of ERP residual disease had either teratoma or viable disease on final pathology. Five-year probability of freedom from progression was 74% (95% CI 65%, 82%) and disease-specific survival was 84% (95% CI 75%, 89%). On multivariable analysis the histologic findings at the ERP site were significant predictors of disease progression, independent of the RP findings. Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.

Original languageEnglish
Pages (from-to)156-159
Number of pages4
JournalUrology
Volume79
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Germ Cell and Embryonal Neoplasms
Testicular Neoplasms
Teratoma
Survival
Lymph Node Excision
Drug Therapy
Platinum
Disease Progression
Neoplasms
Histology
Fibrosis
Regression Analysis
Nonseminomatous germ cell tumor
Pathology

ASJC Scopus subject areas

  • Urology

Cite this

Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. / Masterson, Timothy; Shayegan, Bobby; Carver, Brett S.; Bajorin, Dean F.; Feldman, Darren R.; Motzer, Robert J.; Bosl, George J.; Sheinfeld, Joel.

In: Urology, Vol. 79, No. 1, 01.2012, p. 156-159.

Research output: Contribution to journalArticle

Masterson, T, Shayegan, B, Carver, BS, Bajorin, DF, Feldman, DR, Motzer, RJ, Bosl, GJ & Sheinfeld, J 2012, 'Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer', Urology, vol. 79, no. 1, pp. 156-159. https://doi.org/10.1016/j.urology.2011.09.038
Masterson, Timothy ; Shayegan, Bobby ; Carver, Brett S. ; Bajorin, Dean F. ; Feldman, Darren R. ; Motzer, Robert J. ; Bosl, George J. ; Sheinfeld, Joel. / Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. In: Urology. 2012 ; Vol. 79, No. 1. pp. 156-159.
@article{bcf33761767840fc9c2c59a32cff2270,
title = "Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer",
abstract = "Integration of platinum-based chemotherapy and surgical resection of residual masses is essential in the management of advanced nonseminomatous germ cell tumors (NSGCT). We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival. Between 1989 and 2003, 532 patients with advanced NSGCT underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) with a median follow-up of 41 months. Survival probabilities were estimated by the KaplanMeier method. Cox proportional hazards regression analysis was used to determine the prognostic significance of risk factors for progression and survival. Of 532 patients, 402 (76{\%}) underwent PC-RPLND alone, and 130 (24{\%}) underwent resection of ERP residual disease concurrently or in a staged fashion within 6 weeks. Concordance between retroperitoneal (RP) and ERP sites of disease was 83{\%} in the presence of fibrosis, 42{\%} for teratoma, and 47{\%} for viable NSGCT. Overall, 34{\%} of patients undergoing resection of ERP residual disease had either teratoma or viable disease on final pathology. Five-year probability of freedom from progression was 74{\%} (95{\%} CI 65{\%}, 82{\%}) and disease-specific survival was 84{\%} (95{\%} CI 75{\%}, 89{\%}). On multivariable analysis the histologic findings at the ERP site were significant predictors of disease progression, independent of the RP findings. Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.",
author = "Timothy Masterson and Bobby Shayegan and Carver, {Brett S.} and Bajorin, {Dean F.} and Feldman, {Darren R.} and Motzer, {Robert J.} and Bosl, {George J.} and Joel Sheinfeld",
year = "2012",
month = "1",
doi = "10.1016/j.urology.2011.09.038",
language = "English",
volume = "79",
pages = "156--159",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer

AU - Masterson, Timothy

AU - Shayegan, Bobby

AU - Carver, Brett S.

AU - Bajorin, Dean F.

AU - Feldman, Darren R.

AU - Motzer, Robert J.

AU - Bosl, George J.

AU - Sheinfeld, Joel

PY - 2012/1

Y1 - 2012/1

N2 - Integration of platinum-based chemotherapy and surgical resection of residual masses is essential in the management of advanced nonseminomatous germ cell tumors (NSGCT). We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival. Between 1989 and 2003, 532 patients with advanced NSGCT underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) with a median follow-up of 41 months. Survival probabilities were estimated by the KaplanMeier method. Cox proportional hazards regression analysis was used to determine the prognostic significance of risk factors for progression and survival. Of 532 patients, 402 (76%) underwent PC-RPLND alone, and 130 (24%) underwent resection of ERP residual disease concurrently or in a staged fashion within 6 weeks. Concordance between retroperitoneal (RP) and ERP sites of disease was 83% in the presence of fibrosis, 42% for teratoma, and 47% for viable NSGCT. Overall, 34% of patients undergoing resection of ERP residual disease had either teratoma or viable disease on final pathology. Five-year probability of freedom from progression was 74% (95% CI 65%, 82%) and disease-specific survival was 84% (95% CI 75%, 89%). On multivariable analysis the histologic findings at the ERP site were significant predictors of disease progression, independent of the RP findings. Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.

AB - Integration of platinum-based chemotherapy and surgical resection of residual masses is essential in the management of advanced nonseminomatous germ cell tumors (NSGCT). We reviewed our institutional experience in patients undergoing resection of extraretroperitoneal (ERP) residual masses after chemotherapy to assess its impact on cancer progression and survival. Between 1989 and 2003, 532 patients with advanced NSGCT underwent postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) with a median follow-up of 41 months. Survival probabilities were estimated by the KaplanMeier method. Cox proportional hazards regression analysis was used to determine the prognostic significance of risk factors for progression and survival. Of 532 patients, 402 (76%) underwent PC-RPLND alone, and 130 (24%) underwent resection of ERP residual disease concurrently or in a staged fashion within 6 weeks. Concordance between retroperitoneal (RP) and ERP sites of disease was 83% in the presence of fibrosis, 42% for teratoma, and 47% for viable NSGCT. Overall, 34% of patients undergoing resection of ERP residual disease had either teratoma or viable disease on final pathology. Five-year probability of freedom from progression was 74% (95% CI 65%, 82%) and disease-specific survival was 84% (95% CI 75%, 89%). On multivariable analysis the histologic findings at the ERP site were significant predictors of disease progression, independent of the RP findings. Our data suggest that teratoma or viable NSGCT is present in approximately one-third of patients undergoing resection of residual ERP disease. The presence of residual ERP teratoma and viable NSGCT predicts for cancer progression independent of RP histology.

UR - http://www.scopus.com/inward/record.url?scp=84555189364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84555189364&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2011.09.038

DO - 10.1016/j.urology.2011.09.038

M3 - Article

VL - 79

SP - 156

EP - 159

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -